Medtronic ($MDT) and Boston Scientific ($BSX) are making strides AGAINST pain, each gaining FDA approvals for new pain management devices.
On the other hand, $BSX and Becton Dickinson ($BD) are FEELING the pain: $BSX announced a sensor glitch that can cause pacemaker malfunctions and $BD received a sharp warning letter following a two-month FDA investigation.
Medtronic (MDT) Granted FDA Approval for Innovative Clinician Programmer for the Medtronic SynchroMed II Intrathecal Drug Delivery System for Chronic Pain and Severe Spasticity
StreetInsider ($MDT)
Boston Scientific (BSX) Reports Positive Results from WHISPER Spinal Cord Stimulation Study
StreetInsider ($BSX)
FDA approves Boston Scientific’s Spectra WaveWriter chronic pain device
Brad Perriello, Mass Device ($BSX)
FDA slams Becton Dickinson for 510(k) failing, GMP violations in hard-hitting warning letter
Nick Paul Taylor, FierceBiotech ($BDX)
Sensor glitch prompts Boston Scientific warning on pacemakers
Brad Perriello, Mass Device ($BSX)